Korea’s Clinical Trial Landscape In 2022: Approvals Fall To Pre-COVID Levels
MSD, Janssen, Chong Kun Dang, Daewoong Top Sponsors
The Pink Sheet takes an infographic look at South Korea's clinical trial trends in 2022 to illustrate how the country's biopharma R&D is developing and how activities are recovering in the post-pandemic situation. One key takeaway is that approvals for trial starts have fallen back to pre-COVID levels, suggesting a falling off of activity related to drugs and vaccines for the virus.
You may also be interested in...
Lilly Looks For Japan Rebound After Hit From LOEs
Although Lilly Japan's 2022 sales declined 13% on the losses of exclusivity for two important products, the subsidiary has high hopes for three new drugs and other indication expansions. Its first-ever decentralized clinical trial involving Japanese patients, for Alzheimer's candidate donanemab, also turned out successfully.
Kanaph CEO On Surviving The Biotech Funding 'Barley Hump'
The CEO of Korean bioventure Kanaph Therapeutics, Byoung Chul Lee, talks to Scrip about the difficulties such companies are going through amid generally weak investor sentiment, as well as the company's own financing and R&D plans.
Emocog Setting The Standard For Cognitive Decline DTx in Korea
In a little over two years, the Korean bio-digital healthcare platform company Emocog has moved its digital therapeutic for mild cognitive impairment into pivotal clinical trials and is discussing possible collaborations with big pharma firms, CEO Yoo Hun Noh tells Scrip.